4//SEC Filing
KDev Investments AB 4
Accession 0001123292-19-001212
CIK 0001781983other
Filed
Oct 6, 8:00 PM ET
Accepted
Oct 7, 7:33 PM ET
Size
16.2 KB
Accession
0001123292-19-001212
Insider Transaction Report
Form 4
KDev Investments AB
10% Owner
Transactions
- Conversion
Common Stock
2019-10-07+1,600,559→ 2,444,837 total(indirect: See Footnote) - Conversion
Series A Convertible Preferred Stock
2019-10-07−579,647→ 0 total(indirect: See footnote)→ Common Stock (579,647 underlying) - Conversion
Series C Convertible Preferred Stock
2019-10-07−430,467→ 0 total(indirect: See footnote)→ Common Stock (430,467 underlying) - Conversion
Series B Convertible Preferred Stock
2019-10-07−590,445→ 0 total(indirect: See footnote)→ Common Stock (590,445 underlying)
Karolinska Development AB
10% Owner
Transactions
- Conversion
Common Stock
2019-10-07+1,600,559→ 2,444,837 total(indirect: See Footnote) - Conversion
Series A Convertible Preferred Stock
2019-10-07−579,647→ 0 total(indirect: See footnote)→ Common Stock (579,647 underlying) - Conversion
Series B Convertible Preferred Stock
2019-10-07−590,445→ 0 total(indirect: See footnote)→ Common Stock (590,445 underlying) - Conversion
Series C Convertible Preferred Stock
2019-10-07−430,467→ 0 total(indirect: See footnote)→ Common Stock (430,467 underlying)
KCIF Co-Investment Fund KB
10% Owner
Transactions
- Conversion
Common Stock
2019-10-07+1,600,559→ 2,444,837 total(indirect: See Footnote) - Conversion
Series A Convertible Preferred Stock
2019-10-07−579,647→ 0 total(indirect: See footnote)→ Common Stock (579,647 underlying) - Conversion
Series B Convertible Preferred Stock
2019-10-07−590,445→ 0 total(indirect: See footnote)→ Common Stock (590,445 underlying) - Conversion
Series C Convertible Preferred Stock
2019-10-07−430,467→ 0 total(indirect: See footnote)→ Common Stock (430,467 underlying)
Footnotes (3)
- [F1]The amount of securities of Aprea Therapeutics, Inc. (the "Issuer") reported as beneficially owned includes shares held of record by: KDev Investments AB, Karolinska Development AB and KCIF Co-Investment Fund KB (collectively, the "Reporting Persons").
- [F2]Shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.001, on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.
- [F3]Karolinska Development AB ("Karolinska") is the majority owner and co-manager of KDev Investments AB and a limited partner of KCIF Co-Investment Fund KB. Karolinska and each of the other Reporting Persons disclaim beneficial ownership of any shares of the Issuer's Common Stock owned of record by any of the other Reporting Persons except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that any such entity is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The address of each of (i) KDev Investments AB, (ii) Karolinska Development AB, and (iii) KCIF Co-Investment Fund KB is Tomtebodavagen 23A, SE 171 65 Solna, Sweden.
Documents
Issuer
Aprea Therapeutics, Inc.
CIK 0001781983
Entity typeother
IncorporatedSweden
Related Parties
1- filerCIK 0001789888
Filing Metadata
- Form type
- 4
- Filed
- Oct 6, 8:00 PM ET
- Accepted
- Oct 7, 7:33 PM ET
- Size
- 16.2 KB